SGP
NASDAQ HealthcareSpyGlass Pharma, Inc. - Common Stock
Biotechnology
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
๐ Market Data
| Price | $29.08 |
|---|---|
| Volume | 613,826 |
| Market Cap | 972.67M |
| RSI (14-Day) | 69.1 |
| 50-Day MA | $24.75 |
| 52-Week High | $32.44 |
| 52-Week Low | $17.06 |
| Forward P/E | -10.70 |
| Price / Book | 4.19 |
๐ฏ Investment Strategy Scores
SGP scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (94/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SGP in your text
Paste any article, transcript, or post โ the tool will extract SGP and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.